GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (NAS:BIIB) » Definitions » EBITDA

Biogen (Biogen) EBITDA

: $2,039 Mil (TTM As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

Biogen's EBITDA for the three months ended in Dec. 2023 was $503 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $2,039 Mil.

During the past 12 months, the average EBITDA Growth Rate of Biogen was -53.20% per year. During the past 3 years, the average EBITDA Growth Rate was -29.20% per year. During the past 5 years, the average EBITDA Growth Rate was -21.60% per year. During the past 10 years, the average EBITDA Growth Rate was -3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Biogen was 201.30% per year. The lowest was -29.20% per year. And the median was 23.95% per year.

Biogen's EBITDA per Share for the three months ended in Dec. 2023 was $3.45. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was $14.01.

During the past 12 months, the average EBITDA per Share Growth Rate of Biogen was -53.10% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -26.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -15.60% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Biogen was 161.50% per year. The lowest was -26.70% per year. And the median was 22.65% per year.


Biogen EBITDA Historical Data

The historical data trend for Biogen's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,803.20 5,734.80 2,880.10 4,356.80 2,038.50

Biogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 833.60 613.10 874.60 47.60 503.20

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen EV-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biogen's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Biogen's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Biogen's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, Biogen's EBITDA was $2,039 Mil.

Biogen's EBITDA for the quarter that ended in Dec. 2023 is calculated as

Biogen's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2023, Biogen's EBITDA was $503 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,039 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Biogen  (NAS:BIIB) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Biogen EBITDA Related Terms

Thank you for viewing the detailed overview of Biogen's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (Biogen) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Executives
Priya Singhal officer: Head of Development C/O ZAFGEN, INC., 175 PORTLAND STREET 4TH FL, BOSTON MA 02114
Jane Grogan officer: Head of Research BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Susan Langer director BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Ginger Gregory officer: EVP, Human Resources C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Adam Keeney officer: Head of Corporate Development BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Christopher Viehbacher director, officer: President and CEO C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Susan H Alexander officer: EVP, General Counsel C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Nicole Murphy officer: Head of Pharm Ops and Tech BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Rachid Izzar officer: Head of Alzheimer's Disease BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Chirfi Guindo officer: EVP Glob. Mkt Acc & Cust Innov C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alfred Sandrock officer: Grp SVP, Chief Medical Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Jones William D /ca/ director
Maria C Freire director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jesus B Mantas director BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142

Biogen (Biogen) Headlines

From GuruFocus

Q4 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024